Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Investment analysts at Leerink Partnrs issued their FY2024 EPS estimates for shares of Maze Therapeutics in a research report issued to clients and investors on Tuesday, February 25th. Leerink Partnrs analyst J. Schwartz anticipates that the company will post earnings per share of ($4.93) for the year. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. Leerink Partnrs also issued estimates for Maze Therapeutics' Q4 2024 earnings at ($7.60) EPS, Q1 2025 earnings at ($0.58) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.07) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($2.52) EPS, FY2028 earnings at ($2.72) EPS and FY2029 earnings at ($3.17) EPS.
Several other equities analysts have also commented on MAZE. TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. JPMorgan Chase & Co. initiated coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They set an "overweight" rating and a $30.00 target price on the stock. Guggenheim initiated coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They set a "buy" rating and a $19.00 target price on the stock. Finally, Leerink Partners initiated coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price target for the company. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Maze Therapeutics currently has an average rating of "Buy" and a consensus price target of $25.67.
View Our Latest Stock Report on Maze Therapeutics
Maze Therapeutics Stock Down 3.9 %
Shares of MAZE stock traded down $0.49 on Thursday, hitting $12.23. 141,658 shares of the company's stock traded hands, compared to its average volume of 324,193. Maze Therapeutics has a one year low of $10.08 and a one year high of $17.00.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Articles
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
